TD Cowen analyst Charles Rhyee maintained a Buy rating on BrightSpring Health Services, Inc. today and set a price target of $42.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles Rhyee has given his Buy rating due to a combination of factors including BrightSpring Health Services’ strong fundamentals and promising outlook for 2026. Despite some short-term momentum possibly stalling after a significant increase in share price, the company remains well-positioned with robust performance in its pharmaceutical segment. The company has shown consistent growth, with mid-teens EBITDA growth anticipated, which is higher than the consensus estimate.
BrightSpring Health Services has demonstrated strong performance in its specialty and infusion revenues, with significant year-over-year increases. The management’s positive outlook for 2026, driven by continued specialty strength and stable to slightly increasing pharmaceutical margins, further supports the Buy rating. The company’s ability to exceed expectations in total, pharmacy, and provider EBITDA also highlights its operational strength, making it a compelling investment opportunity according to Rhyee.
In another report released on October 23, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $36.00 price target.